COVID-19 No.1
Alternative Names: COVID-19 No.1 - JECHO Biopharmaceuticals; COVID-19-No.1Latest Information Update: 11 Jul 2023
At a glance
- Originator JECHO Biopharmaceuticals
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 11 Jul 2023 Phase-I clinical trials in COVID-2019 infections in China (Parenteral) before July 2023 (JECHO Biopharmaceuticals pipeline, July 2023)
- 23 Mar 2020 Preclinical trials in COVID-2019 infections in China (Parenteral) before March 2020
- 23 Mar 2020 China's NMPA approves IND application of COVID-19 No.1 in COVID-2019 infections in China